Success Metrics

Clinical Success Rate
77.1%

Based on 54 completed trials

Completion Rate
77%(54/70)
Active Trials
15(15%)
Results Posted
87%(47 trials)
Terminated
16(16%)

Phase Distribution

Ph phase_2
29
29%
Ph phase_3
32
32%
Ph phase_4
23
23%
Ph early_phase_1
1
1%
Ph phase_1
4
4%
Ph not_applicable
11
11%

Phase Distribution

5

Early Stage

29

Mid Stage

55

Late Stage

Phase Distribution100 total trials
Early Phase 1First-in-human
1(1.0%)
Phase 1Safety & dosage
4(4.0%)
Phase 2Efficacy & side effects
29(29.0%)
Phase 3Large-scale testing
32(32.0%)
Phase 4Post-market surveillance
23(23.0%)
N/ANon-phased studies
11(11.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.0%

54 of 74 finished

Non-Completion Rate

27.0%

20 ended early

Currently Active

15

trials recruiting

Total Trials

101

all time

Status Distribution
Active(17)
Completed(54)
Terminated(20)
Other(10)

Detailed Status

Completed54
Terminated16
unknown10
Recruiting9
Active, not recruiting6
Withdrawn4

Development Timeline

Analytics

Development Status

Total Trials
101
Active
15
Success Rate
77.1%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (1.0%)
Phase 14 (4.0%)
Phase 229 (29.0%)
Phase 332 (32.0%)
Phase 423 (23.0%)
N/A11 (11.0%)

Trials by Status

unknown1010%
not_yet_recruiting11%
completed5453%
active_not_recruiting66%
withdrawn44%
recruiting99%
enrolling_by_invitation11%
terminated1616%

Recent Activity

Clinical Trials (101)

Showing 20 of 101 trialsScroll for more
NCT05669001Phase 2

A Study of TCD601 in de Novo Renal Transplant Recipients

Completed
NCT07565844Not Applicable

Intradermal Exosomes, Platelet-Rich Plasma, and Steroids for Post-Herpetic Neuralgia

Recruiting
NCT06585774Phase 3

A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease

Recruiting
NCT05653349Phase 3

Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)

Active Not Recruiting
NCT05123040Phase 1

Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids

Terminated
NCT06388564Phase 2

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

Recruiting
NCT05156710Phase 2

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

Active Not Recruiting
NCT04877288Phase 3

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Recruiting
NCT07340723Phase 2

Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )

Recruiting
NCT06521762Phase 2

Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis

Withdrawn
NCT03292861Phase 2

The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients

Enrolling By Invitation
NCT05468320Phase 3

Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura

Completed
NCT07297914Phase 2

Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL

Not Yet Recruiting
NCT05643638Phase 2

A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

Recruiting
NCT03721965Phase 1

Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects

Terminated
NCT01059786Phase 2

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Active Not Recruiting
NCT06019507Phase 2

A Study of TCD601 in the Induction of Tolerance in de Novo Liver Transplantation

Active Not Recruiting
NCT00933231Phase 3

Comparison of Standard Versus Low Dose Advagraf® With or Without Angiotensin-converting Enzyme Inhibitor (ACEi)/Angiotensin Receptor Blocker (ARB) on Histology and Function of Renal Allografts

Completed
NCT01304836Phase 4

A Study Looking at Diabetes in Kidney Transplant Recipients Receiving Immunosuppressive Regimen With or Without Steroids

Completed
NCT01011205Phase 3

Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation

Completed

Drug Details

Intervention Type
DRUG
Total Trials
101